Sec Form 4 Filing - Talbot George Harrison @ Nabriva Therapeutics AG - 2017-02-16

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Talbot George Harrison 2. Issuer Name and Ticker or Trading Symbol Nabriva Therapeutics AG [ NBRV] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 1000 CONTINENTAL DRIVE, SUITE 600 3. Date of Earliest Transaction (MM/DD/YY) 02/16/2017 (Street) KING OF PRUSSIA, PA19406 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Shares 02/16/2017( 1 ) M 502 A 3,351 D Common Shares 02/16/2017( 1 ) M 155 A 3,506 D Common Shares 02/16/2017( 1 ) M 578 A 4,084 D Common Shares ( 3 ) 05/15/2017 S 50 D $ 101.5 ( 4 ) 4,034 D Common Shares ( 3 ) 05/16/2017 S 50 D $ 102.268 ( 5 ) 3,984 D Common Shares ( 3 ) 05/16/2017 S 100 D $ 103 ( 6 ) 3,884 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Tran saction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option ( 2 ) 02/16/2017( 1 ) M 502 ( 7 ) 09/27/2017 Common Shares 502 $ 0 0 D Stock Option ( 2 ) 02/16/2017( 1 ) M 155 ( 8 ) 09/27/2017 Common Shares 155 $ 0 0 D Stock Option ( 2 ) 02/16/2017( 1 ) M 578 ( 9 ) 09/27/2017 Common Shares 578 $ 0 135 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Talbot George Harrison 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA, PA19406 X Signatures /s/ Gary L. Sender, by power of attorney 05/17/2017 Signature of Reporting Person Date

Explanation of Responses:

( 1 )This transaction is being reported late due to an administrative oversight. ( 2 )The exercise price was Euro 6.72 per common share. ( 3 )The common shares whose sale is reported on this line are represented by American Depositary Shares ("ADSs"). Each ADS represents one tenth (1/10) of a common share of Nabriva Therapeutics AG. The reporting person may hold both common shares and ADSs representing common shares, and Column 5 reports such holdings on an aggregate basis in terms of the corresponding number of common shares. ( 4 )The price of $101.50 per common share was derived from the sale price on May 15, 2017, of $10.15 per ADS, multiplied by ten. ( 5 )The price of $102.268 per common share was derived from the sale price on May 16, 2017, of $10.2268 per ADS, multiplied by ten. ( 6 )The price of $103.00 per common share was derived from the sale price on May 16, 2017, of $10.30 per ADS, multiplied by ten. ( 7 )This option was granted on June 12, 2009 and is fully vested. ( 8 )This option was granted on January 29, 2010 and is fully vested. ( 9 )This option was granted on August 31, 2014. Vesting began on August 31, 2014 and ends on September 30, 2017. Twenty-five percent (25%) of the option vested on December 31, 2014, a further twenty-five percent (25%) of the options vested on December 31, 2015, and the remaining fifty percent (50%) vests on a monthly pro-rata basis over the remaining vesting period.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.